Patients with active collagenous colitis were randomly assigned to groups given pH-modified release oral budesonide capsules ( 9 mg budesonide once daily , Budenofalk , n = 30 ) , mesalamine granules ( 3 g mesalamine once daily , Salofalk , n = 25 ) , or placebo for 8 weeks ( n = 37 ) in a double-blind , double-dummy fashion .